Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02481414 · ClinicalTrials.gov registry record · Phase 2
A Clinical Trial of PepCan to Two Therapy Arms for Treating Cervical High-Grade Squamous Intraepithelial Lesions
A Phase 2 study of Cervical Intraepithelial Neoplasia, sponsored by University of Arkansas.
- Completed
- Registry status
- Phase 2
- Development phase
- 81
- Enrollment target
- 1
- Study location
NCT02481414: Completed Phase 2 study of Cervical Intraepithelial Neoplasia, sponsored by University of Arkansas.
NCT02481414 is a Phase 2 study of Cervical Intraepithelial Neoplasia that has completed, run by University of Arkansas. The registered enrollment target is 81 participants, below the 257-participant average among 6 other Cervical Intraepithelial Neoplasia trials with a reported enrollment target (68% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02481414, a Phase 2 study of Cervical Intraepithelial Neoplasia, has completed, sponsored by University of Arkansas.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 81 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a Phase II study to evaluate the efficacy and safety of a human papilloma virus (HPV) therapeutic vaccine called PepCan (HPV 16 E6 peptides combined with Candida skin testing reagent called Candin®) in adult females over a 12 month time period. As the results from the Phase I trial demonstrated some efficacy against non-16 HPV types, Candin alone will also be tested. Therefore, there will be two treatment arms: (1) PepCan and (2) Candin. Subjects found to be eligible for vaccination will be randomized in a double-blinded fashion at a 1:1 ratio. Each participant will be receiving injections four times with three weeks between injections. Clinical and virological responses will be assessed at 6 and 12 months. Safety will be assessed from the time of enrollment to 12 Month Visit. Immunological assessments will be made at 4 time points (prevaccination, after 2 injections, 6 month after 4 injections and 12 months after 4 vaccinations).
Primary Outcome
Histological regression of moderate/severe cervical dysplasia to absence of cervical dysplasia assessed using biopsies (stringent)
Conditions Studied
Interventions
- BIOLOGICAL PepCan
- BIOLOGICAL Candin®
Study Locations (1)
Arkansas
- University of Arkansas for Medical Sciences - Little Rock
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 81 participants |
| Start Date | 2015-11-30 |
| Est. Completion | 2022-09-14 |
| Phase | Phase 2 |
What the finished NCT02481414 record still lists
NCT02481414 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 81 participants, a relatively small participant target, below the 257-participant average among 6 other Cervical Intraepithelial Neoplasia trials with a reported enrollment target (68% lower).
The record links to 1 condition, with Cervical Intraepithelial Neoplasia appearing as the primary indexed condition, and to 2 interventions - of which PepCan is the first listed.
NCT02481414 reports a single indexed study location in Arkansas.
Frequently Asked Questions
What is clinical trial NCT02481414 about?
NCT02481414 is a clinical study titled "A Clinical Trial of PepCan to Two Therapy Arms for Treating Cervical High-Grade Squamous Intraepithelial Lesions". This is a Phase II study to evaluate the efficacy and safety of a human papilloma virus (HPV) therapeutic vaccine called PepCan (HPV 16 E6 peptides combined with Candida skin testing reagent called Candin®) in adult females over a 12 month time period. As the results from the Phase I trial demonstra...
What is the current status of trial NCT02481414?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 81 participants. The study started on 2015-11-30. Estimated completion is 2022-09-14.
What conditions does trial NCT02481414 study?
This clinical trial studies the following conditions: Cervical Intraepithelial Neoplasia.
What interventions are being tested in trial NCT02481414?
The interventions under investigation include: PepCan (BIOLOGICAL), Candin® (BIOLOGICAL).
Who is sponsoring clinical trial NCT02481414?
This trial is sponsored by University of Arkansas, which has 318 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02481414 being conducted?
This trial has 1 study location across Arkansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cervical Intraepithelial Neoplasia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Pembrolizumab for the Treatment of Cervical Intraepithelial Neoplasia
RECRUITING · Phase 2
-
Safety and Efficacy of A-007 Topical Gel in the Treatment of High-Grade Squamous Intraepithelial Lesions (HSIL) of the Cervix
COMPLETED · Phase 2
-
Fenofibrate in Patients With Cervical Intraepithelial Neoplasia and Invasive Cervical Carcinoma
RECRUITING · Phase 1
-
Immunogenicity of Gardasil-9 HPV Vaccine in People Living With HIV
RECRUITING · Phase 4
-
A Novel, Low-Cost, Handheld 3D Imaging System for Improved Screening for Cervical Neoplasia in Resource-Limited Settings
ACTIVE NOT RECRUITING · NA
-
A Study on the Immune Response and Safety of an Adjuvanted Human Papillomavirus Vaccine When Given to Healthy Women 16 to 26 Years of Age
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04966481 · 81 participants · Phase 3
Palbociclib and Cetuximab Versus Cetuximab Monotherapy for Patients With CDKN2A-altered, HPV-unrelated Head and Neck Squamous Cell Carcinoma Who Experienced Disease Progression on a PD-1/L1 Inhibitor
- NCT05109429 · 81 participants · NA
Developing a Clinical Outcome Assessment for Opioid Craving
- NCT05112601 · 81 participants · Phase 2
Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma
- NCT05305911 · 81 participants · Phase 2
Sodium Glucose Co-Transporter 2 (SGLT2) and STEMI
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI